PhaseV to Present Transformative Use of AI for Clinical Development at Upcoming Events

Presentations to Highlight the Power of Advanced Machine Learning for Enhancing Trial Design, Execution and Analysis

BOSTON, April 8, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced its participation in several upcoming biotech and data science conferences. The company will showcase its advancements in optimizing clinical trials using AI-powered analytics, biostatistics, and rigorous trial design to increase efficiency, ensure regulatory adherence, and accelerate treatments for a wide range of diseases, including oncology, inflammatory bowel disease and more.

"As clinical development becomes increasingly complex, integrating AI and advanced statistical modeling is essential to optimize efficiency and deliver results," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "We're excited to showcase how our rigorous scientific approach, unparalleled data assets, and novel use of real-world evidence are reshaping trial design, analysis and execution."

Event participation includes:

• IBD Innovate 2025
  April 9-10, New York, NY
  PhaseV will showcase its advancements in the exhibition hall
  
  
• Duke Industry Statistics Symposium 2025
  April 9-11, Durham, NC
  •  Panel Session: S1D – Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials
  •  Moderator:  Brad Carlin, PhD, Senior Director, Data Science and Statistics at PhaseV
  
  
• Presentations:
  ○  Causal Machine Learning for Estimating Uncertainty and Detecting Subgroups in Adaptive Clinical Trials
  Speaker: Raviv Pryluk, PhD, CEO and Co-founder, PhaseV
  ○  To Bayes or Not to Bayes: Practical Challenges and Considerations in Supporting the Design of Adaptive Clinical Trials
  Speaker: Yaniv Fogel, Algo Team Lead at PhaseV
  
  
• Joint Statistical Meetings (JSM) 2025
  August 2-7, Nashville, TN
  •  Presentations:
  ○  Recent Advances in Computing, Optimization, and Causal Inference for Adaptive Clinical Trials 
  Speakers: Raviv Pryluk, PhD, CEO and Co-founder, PhaseV and Brad Carlin, PhD, Senior Director, Data Science and Statistics at PhaseV
  ○  Innovative Statistical Methods for Robust Analysis from Small Samples
  Speakers:  Elad Berkman, PhD, CTO and Co-founder of PhaseV, Tzviel Frostig, PhD, Senior Data Scientist at PhaseV, Yaron Racah, Algorithms Developer at PhaseV, and Sofia Villar, PhD, Programme Leader at MRC Biostatistics Unit, University of Cambridge

• 13th International Conference on Multiple Comparison Procedures (MCP 2025)
  August 12-15, Philadelphia, PA
  Presentation: Identifying Treatment Responders in Clinical Trials
  Speaker: Tzviel Frostig, PhD, Senior Data Scientist at PhaseV

In addition, Dan Goldstaub, PhD, PhaseV's Scientific Co-founder, and Hamza Sheikh, Head of Business Development, will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 30th to June 2nd.

Since its founding, PhaseV's technology platform has been adopted by more than 30 global pharmaceutical and biotech companies, including industry leaders, to optimize clinical development and advance therapies in complex disease areas.

About PhaseV
PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of trial success by up to 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.

Learn more at www.PhaseVTrials.com and follow us on LinkedIn.

Media Contact: 
Ellie Hanson
FINN Partners for PhaseV
[email protected] 
929-588-2008

Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg

SOURCE PhaseV